The Experts below are selected from a list of 19845 Experts worldwide ranked by ideXlab platform
Diletta Trojan - One of the best experts on this subject based on the ideXlab platform.
-
Stability analysis of the antibiotic cocktail used by Treviso Tissue Bank Foundation for Tissues decontamination.
Cell and Tissue Banking, 2018Co-Authors: Giulia Montagner, Diletta Trojan, Elisa Cogliati, Flavio Manea, Andrea Vantini, Adolfo PaolinAbstract:Although careful donor selection reduces Tissue contamination, close microbiological control of harvested allografts remains a key task of Tissue Banks. To guarantee the safety of human Tissues for allograft transplantation, a decontamination regimen must be adopted which, as recommended by European guidelines, is active against the majority of microorganisms isolated in Tissues. Antibiotic decontamination methods differ from one Tissue Bank to another in terms of antimicrobial agents, temperature and length of exposure. After identifying the most effective antibiotics against the bacterial strains most commonly isolated in allografts, Treviso Tissue Bank Foundation demonstrated the efficacy of an antibiotic cocktail for Tissue decontamination containing Gentamicin, Vancomycin and Meropenem. The aim of this study was to analyse the degradation kinetics of the three antibiotics according to preparation method and use. The results show that only Meropenem is unstable at + 4 °C, while Gentamicin and Vancomycin are valid for over 10 days. We thus established to add Meropenem before the start of the Tissue decontamination phase.
-
evaluation of allograft decontamination with two different antibiotic cocktails at the treviso Tissue Bank foundation
PLOS ONE, 2018Co-Authors: Adolfo Paolin, Lisa Spagnol, Giuseppe Battistella, Diletta TrojanAbstract:Microbiological contamination of retrieved Tissues is a critical aspect of allograft safety and Tissue Banks must continuously implement decontamination procedures to minimize Tissue contamination. In this study we compared the decontamination efficacy of a new antibiotic cocktail (cocktail B: BASE medium with Gentamicin, Meropenem and Vancomycin) with the cocktail previously adopted at Treviso Tissue Bank Foundation (FBTV) (cocktail A: RPMI medium with Ceftazidime, Lincomycin, Polymyxin B and Vancomycin). Two decontamination steps were carried out, the first immediately after retrieval, the second after processing. The contamination rate was calculated before processing (Time 1) and cryopreservation (Time 2) for total Tissues, musculoskeletal Tissues and cardiovascular Tissues, and the bacterial species involved were analyzed. Cocktail A was used to decontaminate 3548 Tissues, of which 266 were cardiovascular and 3282 musculoskeletal Tissues. For cocktail A, total Tissue contamination was 18.6% at Time 1 and 0.9% at Time 2, with 15.7% contaminated musculoskeletal Tissues at Time 1 and 0.4% at Time 2, respectively, while cardiovascular Tissues were 50% contaminated at Time 1 and 6.4% at Time 2. Cocktail B was used to decontaminate 3634 Tissues of which 318 were cardiovascular and 3316 musculoskeletal Tissues. For cocktail B, total Tissue contamination was 8.6% at Time 1 and 0.2% at Time 2, with 7.6% contaminated musculoskeletal Tissues at Time 1 and 0.03% at Time 2, respectively. Contamination of cardiovascular Tissues was 20.4% at Time 1 and 1.9% at Time 2. Intergroup and intragroup contamination rates decreased statistically significantly (p<0.05). Our results have shown that cocktail B was more effective than cocktail A in killing bacteria in both cardiovascular and musculoskeletal Tissues during the two decontamination cycles.
Adolfo Paolin - One of the best experts on this subject based on the ideXlab platform.
-
Stability analysis of the antibiotic cocktail used by Treviso Tissue Bank Foundation for Tissues decontamination.
Cell and Tissue Banking, 2018Co-Authors: Giulia Montagner, Diletta Trojan, Elisa Cogliati, Flavio Manea, Andrea Vantini, Adolfo PaolinAbstract:Although careful donor selection reduces Tissue contamination, close microbiological control of harvested allografts remains a key task of Tissue Banks. To guarantee the safety of human Tissues for allograft transplantation, a decontamination regimen must be adopted which, as recommended by European guidelines, is active against the majority of microorganisms isolated in Tissues. Antibiotic decontamination methods differ from one Tissue Bank to another in terms of antimicrobial agents, temperature and length of exposure. After identifying the most effective antibiotics against the bacterial strains most commonly isolated in allografts, Treviso Tissue Bank Foundation demonstrated the efficacy of an antibiotic cocktail for Tissue decontamination containing Gentamicin, Vancomycin and Meropenem. The aim of this study was to analyse the degradation kinetics of the three antibiotics according to preparation method and use. The results show that only Meropenem is unstable at + 4 °C, while Gentamicin and Vancomycin are valid for over 10 days. We thus established to add Meropenem before the start of the Tissue decontamination phase.
-
evaluation of allograft decontamination with two different antibiotic cocktails at the treviso Tissue Bank foundation
PLOS ONE, 2018Co-Authors: Adolfo Paolin, Lisa Spagnol, Giuseppe Battistella, Diletta TrojanAbstract:Microbiological contamination of retrieved Tissues is a critical aspect of allograft safety and Tissue Banks must continuously implement decontamination procedures to minimize Tissue contamination. In this study we compared the decontamination efficacy of a new antibiotic cocktail (cocktail B: BASE medium with Gentamicin, Meropenem and Vancomycin) with the cocktail previously adopted at Treviso Tissue Bank Foundation (FBTV) (cocktail A: RPMI medium with Ceftazidime, Lincomycin, Polymyxin B and Vancomycin). Two decontamination steps were carried out, the first immediately after retrieval, the second after processing. The contamination rate was calculated before processing (Time 1) and cryopreservation (Time 2) for total Tissues, musculoskeletal Tissues and cardiovascular Tissues, and the bacterial species involved were analyzed. Cocktail A was used to decontaminate 3548 Tissues, of which 266 were cardiovascular and 3282 musculoskeletal Tissues. For cocktail A, total Tissue contamination was 18.6% at Time 1 and 0.9% at Time 2, with 15.7% contaminated musculoskeletal Tissues at Time 1 and 0.4% at Time 2, respectively, while cardiovascular Tissues were 50% contaminated at Time 1 and 6.4% at Time 2. Cocktail B was used to decontaminate 3634 Tissues of which 318 were cardiovascular and 3316 musculoskeletal Tissues. For cocktail B, total Tissue contamination was 8.6% at Time 1 and 0.2% at Time 2, with 7.6% contaminated musculoskeletal Tissues at Time 1 and 0.03% at Time 2, respectively. Contamination of cardiovascular Tissues was 20.4% at Time 1 and 1.9% at Time 2. Intergroup and intragroup contamination rates decreased statistically significantly (p<0.05). Our results have shown that cocktail B was more effective than cocktail A in killing bacteria in both cardiovascular and musculoskeletal Tissues during the two decontamination cycles.
Valerie Speirs - One of the best experts on this subject based on the ideXlab platform.
-
abstract p4 19 05 breast cancer campaign Tissue Bank human cell culture programme generating new biomaterials for breast research
Cancer Research, 2013Co-Authors: J Gomm, Adrienne Morgan, Sally Smith, Linda Haywood, Muge Sarper, S Dreger, A Ironside, E Cortes J Lopez, A Del Rio Hernandez, Valerie SpeirsAbstract:Background: In-vitro model systems provide an important tool in breast cancer research and, over recent years, there have been considerable advances in their construction. However, despite these advances, the majority of models still employ a narrow range of established cell lines, which frequently are not appropriate for the in-vivo cell type they are representing 1 . Method: As part of the Breast Cancer Campaign Tissue Bank, we have developed a cell culture programme which feeds into the main Tissue collection and involves the systematic generation of materials from normal, high-risk, cancer-containing and malignant breast Tissue in order to make available a breadth of material to the research community. Following informed patient consent, fresh Tissue is retrieved and, using Tissue digestion and magnetic bead technology 2 , purified cell populations are isolated, characterized and frozen down, or further processed for DNA and RNA isolation. Results: We have isolated purified populations of luminal epithelial, myoepithelial and fibroblast cells from normal breast, risk-reduction (BRCA1 and BRCA2 mutated) breast and from morphologically normal breast Tissue surrounding breast cancer. We have generated matched surround and tumour-associated fibroblasts, as well as matched tumour epithelial and tumour-associated fibroblast cell isolates. These cells have been incorporated into 2- and 3-D culture models and we have demonstrated successful genetic manipulation, with siRNA gene knockdown and gene over-expression through retroviral transduction. Immortalisation of selected cell populations is currently underway. Intact organoids and Tissue explants have also been generated for in-vitro experimentation. Matched frozen and FFPE samples are available, together with full clinicopathological data. The research community can access these biomaterials via a web-based search portal, with full user support. Conclusion: Through this cell culture programme we aim to make available a wider and more appropriate range of materials for breast research, which should allow more clinically relevant model systems to be developed and add value to breast cancer bioBanking. References: 1. Thompson A., et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research 2008; 10: R26. 2. Gomm J.J. et al. Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads. Analytical Biochemistry 1995; 226: 91-99. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-19-05.
-
abstract p4 19 02 early experience of patient donation and researcher use of Tissues donated to a national breast cancer Tissue Bank
Cancer Research, 2013Co-Authors: Valerie Speirs, I O Ellis, Andrew M Hanby, P Quinlan, Rona Good, B Matharooball, Brian J Thomson, D Lyons, Philip J Coates, Colin A PurdieAbstract:The need for a specialist breast cancer bioBank was recognised through a Gap Analysis conducted by the UK charity, Breast Cancer Campaign (Thompson AM et al., Breast Cancer Res 2008: 10(2); R26). As a result The Breast Cancer Campaign Tissue Bank (www.breastcancerTissueBank.org) was launched in 2010 as a coalition of 4 centres of excellence for breast cancer research in the UK. Breast cancer patients presenting to these centres are offered the opportunity to donate surplus Tissue and bloods to The Breast Cancer Campaign Tissue Bank. Researchers can apply for these samples by completing a simple on line application form. Here we describe our early experience of patient donation to The Breast Cancer Campaign Tissue Bank and outline the sample requests received from researchers to date. Most of the first year of operation (2010) was spent developing SOPs and ensuring collection protocols were robust, with some limited prospective collection. The collection was pump-primed from existing resources. By 2011 all sites were operational and working to the same standards. Over a 2 year period (Jan 2011 - Dec 2012), over 90% of suitable patients (1803) consented to Tissue donation. From these we derived 3951 frozen Tissue aliquots, 1517 formalin-fixed paraffin-embedded cases and 2012 blood derivatives (serum, plasma and whole blood). Asian patients were less likely to consent while younger patients tended not to donate blood, but were happy to donate Tissue. All male patients consented to Tissue and blood donation. At Dec 2012, the total numbers of sample aliquots derived from these donated Tissue and blood samples was 22, 127. This includes frozen and formalin-fixed paraffin-embedded Tissues, serum, plasma and whole blood. At present, application for Tissue samples is restricted to the UK and Ireland but we aim to open to international applications in the near future. All applications are reviewed by an international Tissue Access Committee which includes appropriate clinical and scientific expertise plus representation by patient advocates. At 1st June 2013, seventeen applications had been received, of which 14 were approved. Three applications were rejected, made on the basis that the applicants were not making the best use of the donated material. Thus far, Tissues have been dispatched to 9 researchers with 5 in preparation. These include 465 formalin-fixed paraffin-embedded cases and 158 frozen samples, all provided with a basic minimum dataset. Early experience of patient consent was encouraging with patients overall very enthusiastic and willing to donate to our bioBanking programme. More research is needed to help understand the barriers in preventing ethnic minorities to donate and the reluctance in some young people to donate blood samples. Interest by the breast cancer research community in accessing samples is steadily rising as the resource becomes more widely known and increased website traffic is translating into applications for Tissues. This has been an ambitious multidisciplinary endeavour but we are building a valuable resource to service the needs of the breast cancer research community with the goal of helping translate laboratory results into clinical benefit. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-19-02.
-
p5 21 03 the breast cancer campaign Tissue Bank
Cancer Research, 2011Co-Authors: Louise Jones, Claude Chelala, I O Ellis, U Ekbote, Andrew R Green, Andrew M Hanby, Lee B Jordan, Colin A Purdie, P Quinlan, Valerie SpeirsAbstract:The breast cancer research community has recognised that access to a source of carefully collected well-annotated human breast Tissue is essential for translational research. Research institutions often face barriers in gaining access to this resource as collections typically have restrictive access policies or an over burdensome application process. This was formally recognised by around 50 prominent breast cancer researchers through a Gap Analysis conducted in London, UK in 2006 1 . As a direct result of this report, 4 leading UK centres (Barts Cancer Institute, the Universities of Dundee, Leeds and Nottingham) with multi disciplinary expertise in pathology, basic science, bioinformatics and computer science have collaborated with a leading breast cancer charity to form the Breast Cancer Campaign Tissue Bank (BCCTB; http://www.breastcancercampaignTissueBank.org). BCCTB is a unique resource of biological materials and supportive clinical data, efficiently and ethically collected from patients with breast cancer, to provide researchers with high quality, relevant materials, helping to raise the standard of breast cancer research and facilitating the co-ordinated translation of scientific findings into the clinical setting. A wide range of biological materials are Banked, including fresh frozen tumour and surrounding Tissue, isolated purified cell populations (which can be provided for culture or DNA/RNA/protein extraction), whole blood and serum samples, as well as formalin-fixed paraffin-embedded material. Specialised collections are also available through the Bank on a collaborative basis. BCCTB has a centralised IT system allowing efficient tracking of samples and recording of raw data from studies, and providing a user-friendly web-based search portal to view material available. A purpose-built Bioinformatics platform allows mining breast cancer literature data from multiple sources and integrating different types of -omics and clinical data alongside publically relevant annotations from a growing number of biological resources such as NCBI, Ensembl, UniProt and Reactome. This platform is also fully interoperable with the International Cancer Genome Consortium (ICGC) and can be automatically cross-queried from the ICGC data portal which allows direct cross-comparison of experimental findings generated from the ICGC breast cancer projects with literature-derived information stored in our portal. Together this results in the highly efficient and co-ordinated use of samples, reducing duplication of effort and facilitating data mining and analysis. As science is constantly evolving we have an inbuilt RD71(24 Suppl):Abstract nr P5-21-03.
J. Wolter Oosterhuis - One of the best experts on this subject based on the ideXlab platform.
-
tubafrost 2 standardising Tissue collection and quality control procedures for a european virtual frozen Tissue Bank network
European Journal of Cancer, 2006Co-Authors: M M Morente, Reinhard Mager, Alan Spatz, K Knox, D J Kerr, S Alonso, Winand N. M. Dinjens, Francesco Pezzella, J. Wolter OosterhuisAbstract:Tumour Bank Networking presents a great challenge for oncological research as in order to carry out large-scale, multi-centre studies with minimal intrinsic bias, each tumour Bank in the network must have some fundamental similarities and be using the same standardised and validated procedures. The European Human Frozen Tumour Tissue Bank (TuBaFrost) has responded to this need by the promotion of an integrated platform of tumour Banks in Europe. The operational framework for TuBaFrost has drawn upon the best practice of standard workflows and operating procedures employed by members of the TuBaFrost project and key initiatives worldwide.
Reinhard Mager - One of the best experts on this subject based on the ideXlab platform.
-
tubafrost 2 standardising Tissue collection and quality control procedures for a european virtual frozen Tissue Bank network
European Journal of Cancer, 2006Co-Authors: M M Morente, Reinhard Mager, Alan Spatz, K Knox, D J Kerr, S Alonso, Winand N. M. Dinjens, Francesco Pezzella, J. Wolter OosterhuisAbstract:Tumour Bank Networking presents a great challenge for oncological research as in order to carry out large-scale, multi-centre studies with minimal intrinsic bias, each tumour Bank in the network must have some fundamental similarities and be using the same standardised and validated procedures. The European Human Frozen Tumour Tissue Bank (TuBaFrost) has responded to this need by the promotion of an integrated platform of tumour Banks in Europe. The operational framework for TuBaFrost has drawn upon the best practice of standard workflows and operating procedures employed by members of the TuBaFrost project and key initiatives worldwide.
